MannKind/$MNKD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MannKind
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Ticker
$MNKD
Sector
Primary listing
Employees
592
Headquarters
Website
MannKind Metrics
BasicAdvanced
$702M
114.00
$0.02
0.93
-
Price and volume
Market cap
$702M
Beta
0.93
52-week high
$6.51
52-week low
$2.25
Average daily volume
7.6M
Financial strength
Current ratio
1.705
Quick ratio
1.407
Long term debt to equity
-827.373
Total debt to equity
-922.857
Interest coverage (TTM)
1.22%
Profitability
EBITDA (TTM)
58.834
Gross margin (TTM)
74.79%
Net profit margin (TTM)
1.68%
Operating margin (TTM)
13.34%
Effective tax rate (TTM)
-316.70%
Revenue per employee (TTM)
$590,000
Management effectiveness
Return on assets (TTM)
4.91%
Return on equity (TTM)
-9.03%
Valuation
Price to earnings (TTM)
114
Price to revenue (TTM)
1.793
Price to book
-13.76
Price to tangible book (TTM)
-1.58
Price to free cash flow (TTM)
45.706
Free cash flow yield (TTM)
2.19%
Free cash flow per share (TTM)
0.05
Growth
Revenue change (TTM)
22.23%
Earnings per share change (TTM)
-80.00%
3-year revenue growth (CAGR)
51.80%
3-year earnings per share growth (CAGR)
-61.11%
10-year earnings per share growth (CAGR)
-41.87%
What the Analysts think about MannKind
Analyst ratings (Buy, Hold, Sell) for MannKind stock.
MannKind Financial Performance
Revenues and expenses
MannKind Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MannKind stock?
MannKind (MNKD) has a market cap of $702M as of March 26, 2026.
What is the P/E ratio for MannKind stock?
The price to earnings (P/E) ratio for MannKind (MNKD) stock is 114 as of March 26, 2026.
Does MannKind stock pay dividends?
No, MannKind (MNKD) stock does not pay dividends to its shareholders as of March 26, 2026.
When is the next MannKind dividend payment date?
MannKind (MNKD) stock does not pay dividends to its shareholders.
What is the beta indicator for MannKind?
MannKind (MNKD) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.